AbCellera appoints Sarah Noonberg as first Chief Medical Officer

VANCOUVER - AbCellera Biologics Inc. (NASDAQ:ABCL), a clinical-stage biotechnology company with a market capitalization of $1.27 billion, has appointed Sarah Noonberg, M.D., Ph.D., as its first Chief Medical Officer, the company announced in a press release. According to InvestingPro analysis, AbCellera maintains a strong balance sheet with more cash than debt, positioning it well for clinical development expansion.

Dr. Noonberg, a board-certified physician-scientist, brings over 20 years of industry experience leading development programs from discovery through global regulatory approvals and commercialization across various therapeutic areas including oncology, neuroscience, rare diseases, gene therapy, and cell therapy.

In her new role, Dr. Noonberg will leverage her clinical development background to advance AbCellera’s pipeline of antibody-based therapeutics as the company transitions to a clinical stage organization.

Prior to joining AbCellera, Dr. Noonberg served as Chief Medical Officer at Metagenomi, where she led the translation of its gene editing platform into a pipeline strategy and contributed to its approximately $100 million initial public offering. Her previous experience includes Chief Medical Officer positions at Maze Therapeutics, Nohla Therapeutics, and Prothena Biosciences, as well as leadership roles at BioMarin and Medivation.

"With more than 20 years of experience in clinical development, Sarah brings deep expertise and proven operational and leadership strength that will be invaluable as we continue to build and advance our clinical pipeline," said Carl Hansen, Ph.D., founder and CEO of AbCellera. The appointment comes as the company’s stock has shown remarkable momentum, with InvestingPro data showing a 92.7% price return over the past six months. Get access to 8 more exclusive ProTips and comprehensive analysis with an InvestingPro subscription.

Dr. Noonberg received her M.D. from the University of California, San Francisco, her Ph.D. in Bioengineering from the University of California, Berkeley, and completed her internal medicine residency at Johns Hopkins Hospital. She currently serves as a board member of Neurogene.

AbCellera focuses on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology. The company maintains a strong liquidity position with a current ratio of 11.07, though InvestingPro data indicates it is not yet profitable. Discover detailed insights and access the comprehensive Pro Research Report, available for AbCellera and 1,400+ other US stocks on InvestingPro.

In other recent news, AbCellera Biologics Inc. has reported second-quarter 2025 revenues of $17.1 million, marking a significant increase from $7.3 million in the same period last year. This revenue figure not only represents a 134% year-over-year growth but also far exceeded analyst expectations, which had projected revenues of $7.45 million. The revenue surge was primarily attributed to a milestone payment related to a Trianni license. Additionally, the company posted a quarterly loss of $0.12 per share, which was better than the anticipated loss of $0.14 per share and an improvement from the previous year’s loss of $0.13 per share.

In another development, AbCellera has dosed the first participants in a Phase 1 clinical trial of ABCL575, an investigational antibody therapy for moderate-to-severe atopic dermatitis. The therapy features Fc-silencing and half-life extension, potentially allowing for dosing once every six months. Benchmark has maintained its Hold rating on AbCellera Biologics, as stated in a recent research note. These developments highlight AbCellera’s transition to a clinical-stage biotechnology firm.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.